Duchenne Muscular Dystrophy (DMD) Treatment Market Size, Share, Opportunities, And Trends By Tests (Blood Test, Molecular, Genetic Testing, Electromyography, Muscle Biopsy), By Treatment (Physical Therapy, Orthopedic Devices, Steroids, Others), And By Geography - Forecasts From 2025 To 2030

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Overview and Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Prevalence

4.5.1. By age group

4.5.2. By gender

4.5.3. By region

4.6. Product Pipeline

4.7. Innovations

5. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY TESTS

5.1. Blood Test

5.2. Molecular Genetic Testing

5.3. Electromyography

5.4. Muscle Biopsy

6. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY TREATMENT

6.1. Physical Therapy

6.2. Orthopedic Devices

6.3. Steroids

6.4. Others

7. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY GEOGRAPHY

7.1. North America

7.1.1. USA

7.1.2. Canada

7.1.3. Mexico

7.2. South America

7.2.1. Brazil

7.2.2. Argentina

7.2.3. Others

7.3. Europe

7.3.1. Germany

7.3.2. France

7.3.3. United Kingdom

7.3.4. Spain

7.3.5. Others

7.4. Middle East and Africa

7.4.1. Saudi Arabia

7.4.2. Israel

7.4.3. Others

7.5. Asia Pacific

7.5.1. China

7.5.2. Japan

7.5.3. South Korea

7.5.4. India

7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Competitive Benchmarking and Analysis

8.2. Recent Investments and Deals

8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Pfizer Inc.

9.2. Sarepta Therapeutics, Inc.

9.3. ReveraGen BioPharma, Inc.

9.4. PTC Therapeutics

9.5. NIPPON SHINYAKU CO., LTD.

9.6. ITALFARMACO S.p.A.

9.7. FibroGen, Inc.

9.8. DAIICHI SANKYO COMPANY, LIMITED.

9.9. Solid Biosciences Inc.

LIST OF FIGURES

LIST OF TABLES